Smad3 Mediates Diabetic Dyslipidemia and Fatty Liver in db/db Mice by Targeting PPARδ

• Published in: International journal of molecular sciences Vol. 24; no. 14; p. 11396
• Main Authors: He, Huijun, Zhong, Yu, Wang, Honglian, Tang, Patrick Ming-Kuen, Xue, Vivian Weiwen, Chen, Xiaocui, Chen, Jiaoyi, Huang, Xiaoru, Wang, Cheng, Lan, Huiyao
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.07.2023; MDPI
• Subjects: Blood sugar; Cholesterol; Diabetes; Diabetic nephropathy; Diagnostic reagents industry; Disease; dyslipidemia; Fatty acids; Fatty liver; Health aspects; High density lipoprotein; Hyperglycemia; Insulin resistance; Lipids; Liver; Metabolic disorders; Physiological aspects; Scientific equipment and supplies industry; Smad3; Smad3 inhibitor; Transforming growth factors; treatment; Type 2 diabetes; United States; China; Smad3 inhibitor; treatment; Smad3; fatty liver; dyslipidemia; diabetes

Transforming growth factor-β (TGF-β)/Smad3 signaling has been shown to play important roles in fibrotic and inflammatory diseases. However, the role of Smad3 in dyslipidemia and non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes remains unclear, and whether targeting Smad3 has a therapeuti...